An exploratory cost-effectiveness study evaluating perioperative immunotherapy in NSCLC concluded that neoadjuvant nivolumab demonstrated superiority over other regimens in patients with PD-L1 expression ≥ 50%, including other immunotherapies and standard of care [21]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.